SFSIG
CLDX icon

San Francisco Sentry Investment Group’s Celldex Therapeutics CLDX Stock Holding History

San Francisco Sentry Investment Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-100
Closed -$27K – 630
2014
Q1 		$27K Hold
100
– – 0.01% 421
2013
Q4 		$36K Hold
100
– – 0.01% 369
2013
Q3 		$53K Hold
100
– – 0.02% 298
2013
Q2 		$23K Buy
+100
New +$19.7K 0.01% 402

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

San Francisco Sentry Investment Group's CLDX Position: Q2 2014 in Review

San Francisco Sentry Investment Group sold out of Celldex Therapeutics (CLDX) in Q2 2014, closing a stake of 100 shares — an estimated $27K sold.

San Francisco Sentry Investment Group first reported a position in CLDX in Q2 2013 and held it in 4 quarters. The position peaked at $53K in Q3 2013. 135 funds tracked by Wall St. Rank hold CLDX as of Q2 2014.

  • San Francisco Sentry Investment Group reported no remaining Celldex Therapeutics position as of Q2 2014 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 100 Celldex Therapeutics shares in Q2 2014, an estimated $27K.
  • San Francisco Sentry Investment Group first reported a position in Celldex Therapeutics in Q2 2013 and held it in 4 quarters.
  • San Francisco Sentry Investment Group's Celldex Therapeutics position peaked at $53K in Q3 2013.
  • 135 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2014.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2014, filed 18 Jul 2014.